O
ORIC Pharmaceuticals
Clinical-stage oncology company developing therapies for cancers resistant to treatment
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical-stage oncology company based in South San Francisco, California, developing therapies that target the mechanisms by which cancers become resistant to treatment. Established in 2014 by cancer researchers from Memorial Sloan Kettering Cancer Center, the company listed on the Nasdaq in April 2020. Its pipeline is built around the concept of overcoming innate, acquired and adaptive resistance in cancer, with candidates designed to restore patients' response to existing therapies. Lead programmes include rinzimetostat (ORIC-944), an allosteric inhibitor of the PRC2 complex being developed for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor targeting EGFR exon 20 and HER2 exon 20 mutations in non-small cell lung cancer. Earlier-stage work continues on additional mechanisms of resistance across solid tumours.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- South San Francisco, United States
- Listing
- IPO 2020
- Employees
- 137
- Open positions
- 4
- Dealroom signal
- 74.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Oncology, Research and Development, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2026 | $264M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | May 2025 | $125M | — | NEA · SR One · Viking Global Investors · Nextech | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$165M | — |
| 2025 | $0 | — | −$142M | — |
| 2024 | $0 | — | −$142M | — |
| 2023 | $0 | — | −$110M | — |
| 2022 | $0 | — | −$82M | — |
| 2021 | $0 | — | −$79M | — |
| 2020 | $0 | — | −$25M | — |
Growth signals
Latest recorded traffic for ORIC Pharmaceuticals is 6.8K monthly website visits, up 30.8% over the last three months. ORIC Pharmaceuticals's team grew 6.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
The Column Group
Series B and later16 investors entered at this stage
Fidelity Investments
Invus- APArrowMark Partners
Casdin Capital
Memorial Sloan - Kettering Cancer Center
City Hill Ventures
EcoR1 Capital
Foresite Capital
OrbiMed
Taiho Pharma
Pfizer
Tavistock Group
Frazier Healthcare Partners
Nextech Invest- VPVenrock Healthcare Capital Partners
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ORIC Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ORIC Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.